| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial
|
Cameron, David
|
|
2017
|
18 |
7 |
p. 929-945
|
artikel
|
| 2 |
Adjuvant capecitabine for HER2-negative breast cancer
|
Burki, Talha Khan
|
|
2017
|
18 |
7 |
p. e375
|
artikel
|
| 3 |
Adjuvant pertuzumab improves early breast cancer outcomes
|
Das, Manjulika
|
|
2017
|
18 |
7 |
p. e378
|
artikel
|
| 4 |
Alectinib surpasses crizotinib for untreated ALK-positive NSCLC
|
Gilbert, Judith A
|
|
2017
|
18 |
7 |
p. e377
|
artikel
|
| 5 |
A persistent puritic rash of the chest
|
Kreuter, Alexander
|
|
2017
|
18 |
7 |
p. e424
|
artikel
|
| 6 |
Ascending role of next-generation ALK inhibitors
|
Costa, Daniel B
|
|
2017
|
18 |
7 |
p. 837-839
|
artikel
|
| 7 |
2017 ASCO Annual Meeting
|
Yaqub, Farhat
|
|
2017
|
18 |
7 |
p. 853-854
|
artikel
|
| 8 |
Beam me up, Jolly
|
Harding, Emilia
|
|
2017
|
18 |
7 |
p. 861
|
artikel
|
| 9 |
BRAF-MEK inhibition in melanoma brain metastases: a new hope
|
Forsyth, Peter A
|
|
2017
|
18 |
7 |
p. 836-837
|
artikel
|
| 10 |
Brain Games and Knife Play
|
Blott, Jonathan
|
|
2017
|
18 |
7 |
p. 862
|
artikel
|
| 11 |
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Baselga, José
|
|
2017
|
18 |
7 |
p. 904-916
|
artikel
|
| 12 |
Cancer is Funny
|
Lokody, Isabel
|
|
2017
|
18 |
7 |
p. 859
|
artikel
|
| 13 |
Can lay health workers help prevent oral cancer in Nepal?
|
Shrestha, Aamod Dhoj
|
|
2017
|
18 |
7 |
p. e370
|
artikel
|
| 14 |
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
|
Shaw, Alice T
|
|
2017
|
18 |
7 |
p. 874-886
|
artikel
|
| 15 |
Charged
|
Kinsey, Caroline
|
|
2017
|
18 |
7 |
p. 860-861
|
artikel
|
| 16 |
Chemoimmunotherapy for high-risk neuroblastoma
|
Kushner, Brian H
|
|
2017
|
18 |
7 |
p. 845-846
|
artikel
|
| 17 |
Clinical trials and drug approvals continue to accelerate in China
|
Wang, Mai
|
|
2017
|
18 |
7 |
p. 855
|
artikel
|
| 18 |
Correction to Lancet Oncol 2017; 18: 895–903
|
|
|
2017
|
18 |
7 |
p. e371
|
artikel
|
| 19 |
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial
|
Stebbing, Justin
|
|
2017
|
18 |
7 |
p. 917-928
|
artikel
|
| 20 |
Dabrafenib plus trametinib in patients with BRAF V600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|
Davies, Michael A
|
|
2017
|
18 |
7 |
p. 863-873
|
artikel
|
| 21 |
39 degrees blue
|
Swain, Kelley
|
|
2017
|
18 |
7 |
p. 859-860
|
artikel
|
| 22 |
Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks
|
Del Paggio, Joseph C
|
|
2017
|
18 |
7 |
p. 887-894
|
artikel
|
| 23 |
Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial
|
Allgood, Prue C
|
|
2017
|
18 |
7 |
p. 972-980
|
artikel
|
| 24 |
First-line abiraterone improves survival in prostate cancer
|
Brower, Vicki
|
|
2017
|
18 |
7 |
p. e374
|
artikel
|
| 25 |
From class waivers to precision medicine in paediatric oncology
|
Pearson, Andrew D J
|
|
2017
|
18 |
7 |
p. e394-e404
|
artikel
|
| 26 |
India's generics-only drug policy could put health at risk
|
Gourd, Elizabeth
|
|
2017
|
18 |
7 |
p. e373
|
artikel
|
| 27 |
Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial
|
Mody, Rajen
|
|
2017
|
18 |
7 |
p. 946-957
|
artikel
|
| 28 |
Making precision oncology the standard of care
|
The Lancet Oncology,
|
|
2017
|
18 |
7 |
p. 835
|
artikel
|
| 29 |
Mammography screening: please don't be vague, tell me when I should come!
|
Rossi, Paolo Giorgi
|
|
2017
|
18 |
7 |
p. 848-849
|
artikel
|
| 30 |
Measuring value and benefit—a matter of perspective
|
Evans, William Kenneth
|
|
2017
|
18 |
7 |
p. 839-840
|
artikel
|
| 31 |
Methods to reduce postoperative surgical site infections after head and neck oncology surgery
|
Cannon, Richard B
|
|
2017
|
18 |
7 |
p. e405-e413
|
artikel
|
| 32 |
Misunderstandings, mandatory biopsies, and conflicts of interests in clinical trials: a coercive cocktail?
|
McNeil, Catriona M
|
|
2017
|
18 |
7 |
p. 851-852
|
artikel
|
| 33 |
New WHO Director-General must address cancer control challenges
|
Burki, Talha Khan
|
|
2017
|
18 |
7 |
p. 857
|
artikel
|
| 34 |
Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study
|
Schwalbe, Edward C
|
|
2017
|
18 |
7 |
p. 958-971
|
artikel
|
| 35 |
Olaparib provides benefit in metastatic breast cancer
|
Das, Manjulika
|
|
2017
|
18 |
7 |
p. e376
|
artikel
|
| 36 |
Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
|
Shaverdian, Narek
|
|
2017
|
18 |
7 |
p. 895-903
|
artikel
|
| 37 |
Pricing increases for cancer drugs sparks investigation
|
Venkatesan, Priya
|
|
2017
|
18 |
7 |
p. e372
|
artikel
|
| 38 |
Prophylactic cranial irradiation in small-cell lung cancer
|
Fan, Xingwen
|
|
2017
|
18 |
7 |
p. e368
|
artikel
|
| 39 |
Prophylactic cranial irradiation in small-cell lung cancer
|
Rusthoven, Chad G
|
|
2017
|
18 |
7 |
p. e365
|
artikel
|
| 40 |
Prophylactic cranial irradiation in small-cell lung cancer
|
Manapov, Farkhad
|
|
2017
|
18 |
7 |
p. e366
|
artikel
|
| 41 |
Prophylactic cranial irradiation in small-cell lung cancer
|
Weiss, Glen J
|
|
2017
|
18 |
7 |
p. e367
|
artikel
|
| 42 |
Prophylactic cranial irradiation in small-cell lung cancer – Authors' reply
|
Akamatsu, Hioaki
|
|
2017
|
18 |
7 |
p. e369
|
artikel
|
| 43 |
Radiotherapy and PD-L1 inhibition in metastatic NSCLC
|
De Ruysscher, Dirk
|
|
2017
|
18 |
7 |
p. 840-842
|
artikel
|
| 44 |
Radiotherapy in patients with HIV: current issues and review of the literature
|
Alongi, Filippo
|
|
2017
|
18 |
7 |
p. e379-e393
|
artikel
|
| 45 |
Refining medulloblastoma subgroups
|
Juhnke, Björn-Ole
|
|
2017
|
18 |
7 |
p. 847-848
|
artikel
|
| 46 |
TACT2: improving treatment tolerability in early breast cancer
|
Mathew, Aju
|
|
2017
|
18 |
7 |
p. 843-845
|
artikel
|
| 47 |
Targeted radionuclide therapy in combined-modality regimens
|
Gill, Martin R
|
|
2017
|
18 |
7 |
p. e414-e423
|
artikel
|
| 48 |
Targeting PIK3CA-mutant advanced breast cancer in the clinical setting
|
Chopra, Neha
|
|
2017
|
18 |
7 |
p. 842-843
|
artikel
|
| 49 |
The TNM classification of malignant tumours—towards common understanding and reasonable expectations
|
O'Sullivan, Brian
|
|
2017
|
18 |
7 |
p. 849-851
|
artikel
|
| 50 |
WHA passes resolution on cancer prevention and control
|
Burki, Talha Khan
|
|
2017
|
18 |
7 |
p. 858
|
artikel
|
| 51 |
WHO priority list of medical devices for cancer management
|
Mayor, Susan
|
|
2017
|
18 |
7 |
p. 856
|
artikel
|
| 52 |
Why haven't we cured cancer?
|
Harding, Emilia
|
|
2017
|
18 |
7 |
p. 861-862
|
artikel
|
Tijdschrift beschrijving